Table 5. Comparison of novel... | American Society of Hematology

Table 5.

Comparison of novel immunotherapy approaches in multiple myeloma

	Antibody drug conjugates	Bispecific T-cell engagers	CAR T-cell therapy
Advantages	Off-the-shelf therapy	Off-the-shelf therapy	-
	Immune and nonimmune mechanisms of action	-	-
	Infrequent dosing (every 3 wk-12 wk)	-	One-time therapy
	Encouraging response rates	Deep responses	Deep responses
	No CRS/ICANS	Mostly grade 1-2 CRS/ICANS	-
	Outpatient administration	Only initial dosing as inpatient	Vacation from continuous therapy
Disadvantages	Continuous therapy until progression	Continuous therapy until progression	-
	Frequent dose interruptions	Weekly or biweekly dosing	Administration delays due to manufacturing time
	Ocular toxicity	Significant immunosuppression	Potential for severe CRS/ICANS; prolonged cytopenias
	Ophthalmic exams prior to dosing	Specialized centers required	Complex infrastructure required
	Cost ($$)	Cost ($$)	Cost ($$$)

	Antibody drug conjugates	Bispecific T-cell engagers	CAR T-cell therapy
Advantages	Off-the-shelf therapy	Off-the-shelf therapy	-
	Immune and nonimmune mechanisms of action	-	-
	Infrequent dosing (every 3 wk-12 wk)	-	One-time therapy
	Encouraging response rates	Deep responses	Deep responses
	No CRS/ICANS	Mostly grade 1-2 CRS/ICANS	-
	Outpatient administration	Only initial dosing as inpatient	Vacation from continuous therapy
Disadvantages	Continuous therapy until progression	Continuous therapy until progression	-
	Frequent dose interruptions	Weekly or biweekly dosing	Administration delays due to manufacturing time
	Ocular toxicity	Significant immunosuppression	Potential for severe CRS/ICANS; prolonged cytopenias
	Ophthalmic exams prior to dosing	Specialized centers required	Complex infrastructure required
	Cost ($$)	Cost ($$)	Cost ($$$)

ICANS, immune effector cell-associated neurotoxicity syndrome; wk, week.